Prime Medicine posts corporate deck highlighting prime-editing platform, lead programs in Wilson disease and AATD

Prime Medicine, Inc.

Prime Medicine, Inc.

PRME

0.00
  • Prime Medicine set near-term priorities on in vivo liver programs for Wilson disease and alpha-1 antitrypsin deficiency, using an LNP-delivered Prime Editor.
  • Wilson disease program PM577a: CTA cleared in H1 2026; Phase 1/2 initiation planned in H2 2026; initial clinical data expected in 2027.
  • Alpha-1 antitrypsin deficiency program PM647: IND and/or CTA filing targeted for Q3 2026; Phase 1 start planned; initial data expected in 2027.
  • Ex vivo PM359 for p47phox chronic granulomatous disease: progress toward a BLA filing; commercial launch targeted for 2027+.
  • Pipeline expansion includes in vivo proof-of-concept data in cystic fibrosis in 2026, supported by up to USD 39 million from CF Foundation agreements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.